Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 16, 2026 08:00 ET | Source: ConSynance Therapeutics

ConSynance Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of CSTI-500 for Prader-Willi Syndrome

First patient dosed in FPWR-supported Phase 2a trial of CSTI-500 for hyperphagia and neurobehavioral symptoms in PWS.
March 11, 2019 09:00 ET | Source: ConSynance Therapeutics, Inc.

ConSynance Joins the Prader-Willi Syndrome Clinical Trial Consortium

Rensselaer, New York., March 11, 2019 (GLOBE NEWSWIRE) -- ConSynance Therapeutics, Inc., a clinical-stage biotechnology company developing two innovative treatments for Prader-Willi Syndrome (PWS),...